|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||17.64 / 23.75|
Sample to answer GBS assay offers higher sensitivity and specificity compared to culture
The most recent short interest data was recently released for the 10/14/2016 settlement date, and Luminex Corp is one of the most shorted stocks of the Russell 3000, based on 16.32 "days to cover" versus the median component at 6.24. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
In recent trading, shares of Luminex Corp have crossed above the average analyst 12-month target price of $21.67, changing hands for $21.95/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
The most recent short interest data has been released for the 09/30/2016 settlement date, which shows a 338,203 share decrease in total short interest for Luminex Corp , to 2,811,935, a decrease of 10.74% since 09/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Where some see danger and upheaval, investors see opportunity. And the harrowing Zika virus is no different. Investors are jumping into stocks focused on detecting or wiping out the virus.
PCR-based Assay Runs on the ARIES® System, a Sample to Answer Platform
ARIES platform extension provides the significant benefits of ARIES for clinical labs with lower throughput requirements
Luminex products highlighted in more than 20 poster presentations, and workshop featuring 3 ARIES customers discussing results from their labs
Investors considering a purchase of Luminex Corp shares, but cautious about paying the going market price of $20.04/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put at the $20 strike, which has a bid at the time of this writing of $1.65.
Single Interface for Luminex Data Provides Lab Directors Streamlined Workflow, Improved Data Management, and the Ability to Easily Add New Functionality with Minimal Validation
Trade-Ideas LLC identified Luminex (LMNX) as a strong on high relative volume candidate
New closed-tube, scalable, 96-well solution meets clinical demand for respiratory testing
In trading on Tuesday, shares of Luminex Corp touched a new 52-week high of $21.94/share. That's a 45.78% rise, or $6.89 per share from the 52-week low of $15.05 set back on 02/03/2015.
Recently cleared products will be highlighted at workshops, product demonstrations, events, and posters
Agreement through 2020; Expands Global Distribution of Award-winning Multiplexing Instrumentation
Affymetrix Inc. (NASDAQ: AFFX) and Luminex Corporation (NASDAQ: LMNX) today announced a distribution agreement under which eBioscience, a business unit of Affymetrix, will sell Luminex's MAGPIX ®,...